This paper is in the following e-collection/theme issue:

Grant Proposals (funded, non-ehealth) (69) Clinical Cancer Research (83)

Published on in Vol 4, No 2 (2015): Apr-Jun

Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol

Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol

Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol

Authors of this article:

Bo Jan Noordman1 Author Orcid Image ;   Joel Shapiro1 Author Orcid Image ;   Manon CW Spaander2 Author Orcid Image ;   Kausilia K Krishnadath3 Author Orcid Image ;   Hanneke WM van Laarhoven4 Author Orcid Image ;   Mark I van Berge Henegouwen5 Author Orcid Image ;   Grard AP Nieuwenhuijzen6 Author Orcid Image ;   Richard van Hillegersberg7 Author Orcid Image ;   Meindert N Sosef8 Author Orcid Image ;   Ewout W Steyerberg9 Author Orcid Image ;   Bas PL Wijnhoven1 Author Orcid Image ;   J Jan B van Lanschot1 Author Orcid Image
Article Authors Cited by (58) Tweetations (1) Metrics
All Time | Last Month | Last Six Months | Last Year
There are currently no tweets available for this article within the specified range.